daniluromer (EB01) / Edesa Biotech - LARVOL DELTA

Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis (clinicaltrials.gov) - P2 | N=211 | Completed | Sponsor: Edesa Biotech Inc. | Active, not recruiting ➔ Completed | N=126 ➔ 211

Enrollment change • Trial completion • Contact Dermatitis • Dermatitis • Dermatology • Immunology

A Randomized, Double-Blind, Vehicle-Controlled, Sample Size Adaptive Design Study To Evaluate The Safety And Efficacy Of Topically Applied Eb01 Cream In Adult Subjects With Moderate To Severe Chronic (AAD 2023) - No abstract available

Clinical • Late-breaking abstract

Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis (clinicaltrials.gov) - P2 | N=126 | Active, not recruiting | Sponsor: Edesa Biotech Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Sep 2022 ➔ Mar 2023 | Trial primary completion date: Apr 2022 ➔ Dec 2022

Enrollment closed • Trial completion date • Trial primary completion date • Contact Dermatitis • Dermatitis • Dermatology • Immunology

Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis (clinicaltrials.gov) - P2; N=126; Recruiting; Sponsor: Edesa Biotech Inc.; Trial completion date: Aug 2020 ➔ Sep 2022; Trial primary completion date: May 2020 ➔ Apr 2022

Clinical • Trial completion date • Trial primary completion date • Contact Dermatitis • Dermatitis • Dermatology • Immunology

Edesa Biotech Achieves Enrollment Milestone in Dermatitis Study (Yahoo Finance) - "Edesa Biotech, Inc...today announced that it has completed enrollment of more than 50% of the patients planned for the first cohort of a Phase 2b clinical study evaluating the company's drug candidate as a monotherapy for chronic allergic contact dermatitis....'The patient recruitment rate for our EB01 Phase 2b study in the context of the pandemic is very encouraging. We have now passed the halfway mark for the first cohort and look forward to the trial continuing to progress toward the interim analysis,' said Dr. Nijhawan."

Enrollment status • Contact Dermatitis • Dermatology